What is the latest MAXHEALTH stock price?
The latest stored price for MAXHEALTH is Rs 1,000.00 as of 2026-08-21.
gimli
MAXHEALTH stock AI analysis
MAXHEALTH Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
MAX HEALTHCARE INS LTD is a large-cap stock in Healthcare. This Gimli page shows the latest available MAXHEALTH price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹1,000.00
1W return
-0.85%
1M return
-9.12%
3M return
-8.35%
6M return
-8.08%
1Y return
-20.01%
Market cap
₹97,324.38 cr
PE
67.47
PB
9.06
ROE
+14.33%
ROCE
+14.36%
RSI
32.71
Turnover
₹123.73 cr
Why it can matter in screens
- Momentum: MAXHEALTH is below 50DMA, below 200DMA; RSI is 32.71.
- Returns: 1D +0.21%, 1W -0.85%, 1M -9.12%, 3M -8.35%, 1Y -20.01%.
- Trend levels: 52W high ₹1,167.90, 52W low ₹919.80, off high -14.38%.
- Liquidity: latest turnover is ₹123.73 cr; volume vs 20D is +0.65%.
- Valuation/profitability: PE 67.47, PB 9.06, ROE +14.33%, ROCE +14.36%.
- Growth: 3Y sales CAGR +23.09%, 3Y profit CAGR +9.34%.
Quick Answers
Is MAXHEALTH above its 50DMA and 200DMA?
MAXHEALTH is below 50DMA, below 200DMA. The latest 50DMA is 1,078.87 and the latest 200DMA is 1,049.75.
What are MAXHEALTH PE, ROE and ROCE?
MAXHEALTH has PE 67.47, ROE +14.33%, and ROCE +14.36% in Gimli's latest available snapshot.
How has MAXHEALTH performed recently?
MAXHEALTH has returned -9.12% over 1 month, -8.35% over 3 months, and -20.01% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 2,142.89 cr | 654.26 cr | 342.22 cr | 3.52 |
| 2025-12-31 | 2,067.52 cr | 535.48 cr | 300.92 cr | 3.10 |
| 2025-09-30 | 2,135.47 cr | 608.05 cr | 491.30 cr | 5.05 |
| 2025-06-30 | 2,027.57 cr | 559.42 cr | 307.97 cr | 3.17 |
| 2025-03-31 | 1,909.74 cr | 558.54 cr | 319.00 cr | 3.28 |
| 2024-12-31 | 1,868.31 cr | 458.80 cr | n/a | nan |
| 2024-09-30 | 1,707.46 cr | 491.38 cr | n/a | 2.90 |
| 2024-06-30 | 1,542.95 cr | 422.09 cr | 236.27 cr | 2.43 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 8,373.45 cr | 2,357.21 cr | 1,442.41 cr | 7.33 |
| 2025-03-31 | 7,028.46 cr | 1,930.81 cr | 1,075.88 cr | 11.07 |
| 2024-03-31 | 5,309.48 cr | 1,654.86 cr | 1,057.64 cr | 10.89 |
| 2023-03-31 | 4,488.95 cr | 1,367.23 cr | 1,103.51 cr | 11.38 |
| 2022-03-31 | 1,903.48 cr | 1,050.03 cr | 331.52 cr | 6.25 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 17,230.94 cr | 665.80 cr | 3,478.36 cr | 10,746.63 cr |
| 2025-03-31 | 15,214.48 cr | 661.58 cr | 3,010.29 cr | 9,380.87 cr |
| 2024-03-31 | 11,999.94 cr | 979.84 cr | 1,294.56 cr | 8,408.14 cr |
| 2023-03-31 | 10,101.85 cr | 1,374.33 cr | 908.25 cr | 7,409.59 cr |
| 2022-03-31 | 9,189.13 cr | 309.14 cr | 1,138.62 cr | 6,282.47 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 1,633.32 cr | 148.79 cr | n/a |
| 2025-03-31 | 1,437.96 cr | 493.48 cr | n/a |
| 2024-03-31 | 1,121.67 cr | 335.72 cr | n/a |
| 2023-03-31 | 1,284.13 cr | 948.52 cr | n/a |
| 2022-03-31 | 740.52 cr | 187.18 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +23.71% | +41.78% | +29.96% | +18.68% | +4.56% | +0.00% |
| 2026-03-31 | +23.71% | +45.39% | +26.32% | +16.30% | +4.57% | +0.00% |
| 2025-12-31 | +23.72% | +50.55% | +21.20% | +14.04% | +4.52% | +0.00% |
| 2025-09-30 | +23.74% | +51.80% | +20.03% | +14.25% | +4.43% | +0.00% |
| 2025-06-30 | +23.74% | +54.76% | +17.42% | +12.54% | +4.08% | +0.00% |
| 2025-03-31 | +23.74% | +54.74% | +17.58% | +13.38% | +3.94% | +0.00% |
| 2024-12-31 | +23.74% | +56.93% | +15.55% | +11.72% | +3.77% | +0.00% |
| 2024-09-30 | +23.74% | +57.29% | +15.14% | +11.56% | +3.83% | +0.00% |
| 2024-06-30 | +23.74% | +56.98% | +15.36% | +12.19% | +3.91% | +0.00% |
| 2024-03-31 | +23.75% | +57.33% | +14.96% | +12.33% | +3.96% | +0.00% |
| 2023-12-31 | +23.75% | +60.69% | +11.57% | +10.62% | +3.99% | +0.00% |
| 2023-09-30 | +23.76% | +60.38% | +11.40% | +10.55% | +4.46% | +0.00% |
| 2023-06-30 | +23.76% | +59.89% | +11.90% | +11.32% | +4.46% | +0.00% |
| 2023-03-31 | +23.77% | +51.95% | +19.35% | +18.88% | +4.93% | +0.00% |
| 2022-12-31 | +23.78% | +50.14% | +20.47% | +20.00% | +5.61% | +0.00% |
| 2022-09-30 | +23.80% | +49.27% | +21.17% | +20.86% | +5.76% | n/a |
| 2022-06-30 | +50.64% | +0.00% | +42.76% | n/a | n/a | +51.15% |
| 2022-03-31 | +50.64% | +0.00% | +32.16% | n/a | n/a | +51.15% |
| 2021-12-31 | +60.68% | +0.00% | +32.34% | n/a | n/a | +42.69% |
| 2021-09-30 | +60.91% | +0.00% | +22.93% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze MAX HEALTHCARE INS with valuation, momentum and industry peers
- Compare MAXHEALTH with other Healthcare stocks
- Show large-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View large-cap stocks
- Find stocks above 50DMA
- Compare MAXHEALTH with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.